UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September 22~~October 19, 2023

Seagen Inc.

(Exact name of Registrant as specified in its charter)

Delaware

0-32405

91-1874389

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S Employer

Identification No.)

21823 30th Drive SE

Bothell, Washington 98021

(Address of principal executive offices, including zip code)

(425) 527-4000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001

SGEN

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

OnAs ~~September~~previously disclosed, on March 2212, 2023, Seagen Inc., ~~and Astellas Pharma Inc. issued~~ a ~~press~~Delaware ~~release~~corporation ~~announcing~~(the ~~positive~~“Company”), ~~topline~~entered ~~results~~into ~~from~~an ~~the~~Agreement ~~Phase~~and 3Plan ~~EV-302~~of ~~clinical~~Merger ~~trial~~ (~~also~~the ~~known~~“Merger ~~as KEYNOTE-A39~~Agreement”) ~~for~~by ~~PADCEV®~~and ~~(enfortumab~~among ~~vedotin-ejfv)~~the inCompany, ~~combination~~Pfizer ~~with~~Inc., ~~KEYTRUDA®~~a Delaware corporation (~~pembrolizumab~~“Pfizer”) ~~versus~~and ~~chemotherapy~~Aris inMerger ~~patients~~Sub, ~~with~~Inc., ~~previously~~a ~~untreated~~Delaware ~~locally~~corporation ~~advanced~~and ora ~~metastatic~~wholly ~~urothelial~~owned ~~cancer,~~subsidiary ~~a form~~ of ~~bladder~~Pfizer ~~cancer~~(“Merger ~~that~~Sub”). ~~has~~Pursuant ~~spread~~ to ~~surrounding~~the ~~organs~~Merger ~~or muscles~~Agreement, orMerger ~~other~~Sub ~~parts~~will ofbe ~~the~~merged ~~body. Additional~~with ~~information~~and isinto ~~contained~~the inCompany (the ~~press~~“Merger”), ~~release~~with ~~dated~~the ~~September 22,~~Company ~~2023,~~surviving ~~which~~the isMerger ~~attached~~ as ~~Exhibit~~a ~~99.1~~wholly toowned ~~this~~subsidiary ~~current~~of ~~report and is incorporated by reference herein~~Pfizer.

~~Item~~The 9completion of the Merger is conditioned, among other things, upon receipt of regulatory clearance from the European Commission (the “EC”) under the EU Merger Regulation (the “EUMR”) following referral of jurisdiction pursuant to Article 4(5) EUMR.01 ~~Financial~~The ~~Statements~~EC ~~and~~approved ~~Exhibits~~the Merger unconditionally pursuant to Article 6(1)b EUMR on October 19, 2023.

~~(d)~~The ~~Exhibits~~completion of the Merger remains subject to other customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to the consummation of the Merger, and the satisfaction or waiver of the other closing conditions specified in the Merger Agreement. The Company continues to expect that the Merger will be completed in late 2023 or early 2024.

99.1		Press Release of Seagen Inc. and Astellas Pharma Inc. dated September 22, 2023
104		Cover Page Interactive Data File (formatted as Inline XBRL)

Cautionary Statement Regarding Forward-Looking Statements

~~SIGNATURES~~Certain information set forth herein, including statements as to the expected timing and completion of the proposed transaction among the Company, Pfizer and Merger Sub, constitutes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results or developments may differ materially from those projected or implied in these statements. Such statements include statements about the Company’s expectations. Such statements are based upon the current beliefs and expectations of the management of the Company and are subject to significant risks and uncertainties outside of our control. Among the risks and uncertainties that could cause actual results to differ from those described in the forward-looking statements are the following: the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; the risk that the necessary regulatory approvals may not be obtained or may be obtained subject to conditions that are not anticipated; risks that any of the other closing conditions to the proposed transaction may not be satisfied in a timely manner; risks related to potential litigation brought in connection with the proposed transaction; risks related to financial community and rating agency perceptions of the Company and its business, operations, financial condition and the industry in which it operates; risks related to disruption of management time from ongoing business operations due to the proposed Merger; effects of the announcement, pendency or completion of the proposed Merger on the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with suppliers and partners, and on the Company’s operating results and businesses generally; and risks related to the potential impact of general economic, political and market factors on the parties to the proposed Merger or the proposed Merger.

Discussions of additional risks and uncertainties are contained in the Company’s filings with the SEC. The Company is under no obligation, and expressly disclaims any obligation, to update, alter, or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events, or otherwise. Persons reading this document are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SEAGEN INC.

Date: September 22, 2023

/s/ Jean I. Liu

Date: October 19, 2023

/s/ Jean I. Liu

Jean I. Liu

Chief Legal Officer

Filing Compare · Seagen Inc.